Product Launch Details
NATCO Pharma Limited announces the launch of Carboplatin Injection, a generic version of Paraplatin®, in the U.S. market through its U.S. subsidiary NATCO Pharma USA LLC.
Manufacturing Collaboration
The product launch is executed in manufacturing collaboration with Teyro Labs Pvt Ltd, based in Chennai, India.
Market Context and Impact
The launch addresses a critical shortage of the product in the U.S. market. Carboplatin Injection had estimated sales of USD 27.8 million in the U.S. for the 12 months ending June 2026, according to industry sales data.
Therapeutic Indications
Carboplatin Injection is indicated for the treatment of:
- Advanced ovarian carcinoma
- First-line combination therapy
- Palliative treatment of recurrent disease after prior chemotherapy
Company Background
NATCO Pharma Limited is headquartered in Hyderabad, India and develops, manufactures and distributes:
- Generic and branded pharmaceuticals
- Specialty pharmaceuticals
- Active pharmaceutical ingredients
- Crop protection products
The company is R&D oriented and science driven, with a focus on:
- Leading Oncology player in targeted therapies in domestic market
- Limited competition molecules in the US market
Manufacturing and Regulatory Capabilities
The Company has:
- 9 manufacturing sites in India
- 2 R&D facilities in India
- Manufacturing facilities approved by several leading regulatory authorities including:
- US FDA
- Brazil ANVISA
- Health Canada
- WHO
- Products catering to 50+ global markets